{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:56:35Z","timestamp":1789908995230,"version":"4.0.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["N13-RPIB-0012-03"],"award-info":[{"award-number":["N13-RPIB-0012-03"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"name":"French Minist\u00e8re de l'Enseignement sup\u00e9rieur, de la Recherche et de l'Innovation for Crea-Dev","award":["NA1211012J\/AE AN 11 CC"],"award-info":[{"award-number":["NA1211012J\/AE AN 11 CC"]}]},{"DOI":"10.13039\/501100008222","name":"Universit\u00e9 de Montpellier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008222","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vaincre les Maladies Lysosomales-Suisse"},{"name":"CNRS"},{"name":"NanoMedSyn"},{"name":"Transferts"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.jconrel.2017.10.043","type":"journal-article","created":{"date-parts":[[2017,11,4]],"date-time":"2017-11-04T00:17:09Z","timestamp":1509754629000},"page":"15-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Efficient therapy for refractory Pompe disease by mannose 6-phosphate analogue grafting on acid \u03b1-glucosidase"],"prefix":"10.1016","volume":"269","author":[{"given":"Ilaria","family":"Basile","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afitz","family":"Da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"El Cheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Godefroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Daurat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Harmois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Caillaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry-Vincent","family":"Charbonn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Pau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Gary-Bobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Mor\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Maynadier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9646","key":"10.1016\/j.jconrel.2017.10.043_bb0005","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe's disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jconrel.2017.10.043_bb0010","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00415-012-6636-x","article-title":"Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review","volume":"260","author":"Toscano","year":"2013","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.jconrel.2017.10.043_bb0015","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"issue":"15","key":"10.1016\/j.jconrel.2017.10.043_bb0020","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe's disease","volume":"362","author":"van der Ploeg","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.jconrel.2017.10.043_bb0025","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.nurt.2008.08.009","article-title":"Therapeutic approaches in glycogen storage disease type II\/Pompe disease","volume":"5","author":"Schoser","year":"2008","journal-title":"Neurotherapeutics"},{"issue":"4","key":"10.1016\/j.jconrel.2017.10.043_bb0030","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","article-title":"Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis","volume":"264","author":"Schoser","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.jconrel.2017.10.043_bb0035","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev.bi.61.070192.001515","article-title":"Structure and function of the mannose 6-phosphate\/insulinlike growth factor II receptors","volume":"61","author":"Kornfeld","year":"1992","journal-title":"Annu. Rev. Biochem."},{"issue":"3","key":"10.1016\/j.jconrel.2017.10.043_bb0040","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nrm1050","article-title":"Mannose 6-phosphate receptors: new twists in the tale","volume":"4","author":"Ghosh","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"28","key":"10.1016\/j.jconrel.2017.10.043_bb0045","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.2174\/092986707782794005","article-title":"Mannose 6-phosphate receptor targeting and its applications in human diseases","volume":"14","author":"Gary-Bobo","year":"2007","journal-title":"Curr. Med. Chem."},{"issue":"Pt 3","key":"10.1016\/j.jconrel.2017.10.043_bb0050","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1042\/BJ20050364","article-title":"Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice","volume":"389","author":"Zhu","year":"2005","journal-title":"Biochem. J."},{"issue":"4","key":"10.1016\/j.jconrel.2017.10.043_bb0055","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ymgme.2008.04.009","article-title":"Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease","volume":"94","author":"McVie-Wylie","year":"2008","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.jconrel.2017.10.043_bb0060","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jconrel.2008.12.006","article-title":"In vitro and in vivo evaluation of a non-carbohydrate targeting platform for lysosomal proteins","volume":"135","author":"Stefano","year":"2009","journal-title":"J. Control. Release"},{"issue":"12","key":"10.1016\/j.jconrel.2017.10.043_bb0065","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1021\/bc400365a","article-title":"Glycan structure determinants for cation-independent mannose 6-phosphate receptor binding and cellular uptake of a recombinant protein","volume":"24","author":"Zhou","year":"2013","journal-title":"Bioconjug. Chem."},{"issue":"6","key":"10.1016\/j.jconrel.2017.10.043_bb0070","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/mt.2009.37","article-title":"Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease","volume":"17","author":"Zhu","year":"2009","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.jconrel.2017.10.043_bb0075","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1074\/jbc.M112.438663","article-title":"Glycosylation-independent lysosomal targeting of acid alpha-glucosidase enhances muscle glycogen clearance in pompe mice","volume":"288","author":"Maga","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"16","key":"10.1016\/j.jconrel.2017.10.043_bb0080","first-page":"S38006","article-title":"Phase 1 exploratory efficacy of the novel enzyme replacement therapy NeoGAA in treatment- na\u00efve and alglucosidase alfa-treated late-onset Pompe disease patients","volume":"86","author":"Pena","year":"2015","journal-title":"Neurology"},{"issue":"25","key":"10.1016\/j.jconrel.2017.10.043_bb0085","first-page":"S184","article-title":"Reveglucosidase alfa (BMN701), a GILT-tagged recombinant human acid alpha glucosidase (rhGAA), evaluation in late-onset Pompe disease: preliminary clinical efficacy and safety results of an extension study (72-week results)","author":"Hiwot","year":"2015","journal-title":"Neuromuscul. Disord."},{"issue":"47","key":"10.1016\/j.jconrel.2017.10.043_bb0090","doi-asserted-by":"crossref","first-page":"14774","DOI":"10.1002\/anie.201607824","article-title":"Design of Potent Mannose 6-phosphate analogues for the functionalization of lysosomal enzymes to improve the treatment of Pompe disease","volume":"55","author":"El Cheikh","year":"2016","journal-title":"Angew. Chem. Int. Ed. Eng."},{"issue":"30","key":"10.1016\/j.jconrel.2017.10.043_bb0095","doi-asserted-by":"crossref","first-page":"19086","DOI":"10.1074\/jbc.273.30.19086","article-title":"Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II","volume":"273","author":"Raben","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.jconrel.2017.10.043_bb0100","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1016\/j.bmc.2006.01.024","article-title":"Synthesis and receptor binding affinity of carboxylate analogues of the mannose 6-phosphate recognition marker","volume":"14","author":"Jeanjean","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jconrel.2017.10.043_bb0105","doi-asserted-by":"crossref","first-page":"22683","DOI":"10.1039\/c3ra42960a","article-title":"Structural analysis of glycoprotein sialylation- Part I: pre-LC-MS analytical strategies","volume":"3","author":"Thaysen-Andersen","year":"2013","journal-title":"RSC Adv."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2017.10.043_bb0110","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ymgme.2003.08.022","article-title":"Enzyme replacement therapy in the mouse model of Pompe disease","volume":"80","author":"Raben","year":"2003","journal-title":"Mol. Genet. Metab."},{"issue":"12","key":"10.1016\/j.jconrel.2017.10.043_bb0115","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/labinvest.3700484","article-title":"Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease","volume":"86","author":"Thurberg","year":"2006","journal-title":"Lab. Investig."},{"issue":"6","key":"10.1016\/j.jconrel.2017.10.043_bb0120","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1089\/hum.2008.010","article-title":"Ability of adeno-associated virus serotype 8-mediated hepatic expression of acid alpha-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice","volume":"19","author":"Ziegler","year":"2008","journal-title":"Hum. Gene Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2017.10.043_bb0125","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ymthe.2004.09.017","article-title":"Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers","volume":"11","author":"Raben","year":"2005","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.jconrel.2017.10.043_bb0130","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.nmd.2011.11.003","article-title":"Acid phosphatase-positive globular inclusions is a good diagnostic marker for two patients with adult-onset Pompe disease lacking disease specific pathology","volume":"22","author":"Tsuburaya","year":"2012","journal-title":"Neuromuscul. Disord."},{"issue":"2","key":"10.1016\/j.jconrel.2017.10.043_bb0135","first-page":"424","article-title":"Expression of the insulin-like growth factor-II\/mannose-6-phosphate receptor in multiple human tissues during fetal life and early infancy","volume":"75","author":"Funk","year":"1992","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.jconrel.2017.10.043_bb0140","first-page":"723","article-title":"Quantitation of Mr 46000 and Mr 300000 mannose 6-phosphate receptors in human cells and tissues","volume":"23","author":"Wenk","year":"1991","journal-title":"Biochem. Int."},{"issue":"6","key":"10.1016\/j.jconrel.2017.10.043_bb0145","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ymthe.2006.08.009","article-title":"Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease","volume":"14","author":"Fukuda","year":"2006","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.jconrel.2017.10.043_bb0150","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/emmm.201202176","article-title":"Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease","volume":"5","author":"Spampanato","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.jconrel.2017.10.043_bb0155","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fnagi.2014.00177","article-title":"Pompe disease: from pathophysiology to therapy and back again","volume":"6","author":"Lim","year":"2014","journal-title":"Front. Aging Neurosci."},{"issue":"2","key":"10.1016\/j.jconrel.2017.10.043_bb0160","first-page":"123","article-title":"Pathology of skeletal muscle cells in adult-onset glycogenosis type II (Pompe disease): ultrastructural study","volume":"46","author":"Lewandowska","year":"2008","journal-title":"Folia Neuropathol."},{"issue":"8","key":"10.1016\/j.jconrel.2017.10.043_bb0165","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.4161\/auto.6.8.13378","article-title":"Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder--murine Pompe disease","volume":"6","author":"Raben","year":"2010","journal-title":"Autophagy"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365917309446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365917309446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T12:59:49Z","timestamp":1589806789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365917309446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":33,"alternative-id":["S0168365917309446"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2017.10.043","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficient therapy for refractory Pompe disease by mannose 6-phosphate analogue grafting on acid \u03b1-glucosidase","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2017.10.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}